The influence of combined oral contraceptives on female sexual desire: A systematic review

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 1, 2013, Pages 27-43

  Pastor, Zlatko ^a   Holla, Katerina ^a   Chmel, Roman ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Androgen; Combined oral contraceptives; Female sexuality; Libido; Oestrogen; Sexual desire; Testosterone

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; NORGESTIMATE;

COCHRANE LIBRARY; CORRELATIONAL STUDY; DOSE RESPONSE; DYSPAREUNIA; FEMALE; HUMAN; LIBIDO; MEDLINE; ORAL CONTRACEPTION; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SEXUAL AROUSAL; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUALITY; SIDE EFFECT; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; VAGINAL DRYNESS; VAGINAL LUBRICATION;

CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIBIDO; PLASMA VOLUME; SEX HORMONE-BINDING GLOBULIN; SEXUAL BEHAVIOR;

EID: 84872466587     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2012.728643     Document Type: Review

References (67)

1. Bitzer J, Simon J A. Current issues and available options in combined hormonal contraception. Contraception 2011; 84: 342-56.
2. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010; 15: 4-16.
3. Brotto LA. Current literature review - editorial comment. J Sex Med 2011; 8: 3257.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington: American Psychiatric Press 2000.
5. Basson R, Leiblum S, Brotto L, et al. Definitions of women's sexual dysfunction reconsidered: Advocating expansion and revision. J Psychosom Obstet Gynaecol 2003; 24: 221-9. (Pubitemid 38010480)
6. Davis AR, Castano PM. Oral contraceptives and sexuality. In Goldstein I, Meston C, Davis S, Traish A, eds. Women's sexual function & dysfunction - Study, diagnosis and treatment. London: Taylor & Francis 2006: 290-6.
7. Guay AT, Spark R. Pathophysiology of sex steroids in women. In Goldstein I, Meston C, Davis S, Traish A, eds. Women's sexual function & dysfunction - Study, diagnosis and treatment. London: Taylor & Francis 2006: 218-28.
8. Rabe T, Kowald A, Ortman J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223-30.
9. Traish AM, Kim N N. Modulation of female genital sexual arousal by sex steroid hormones. In Goldstein I, Meston C, Davis S, Traish A, eds. Women's sexual function & dysfunction - Study, diagnosis and treatment. London: Taylor & Francis 2006: 181-93.
10. Warnock JK, Clayton A, Croft H, et al. Comparison of androgens in women with hypoactive sexual desire disorder: Those on combined oral contraceptives (COCs) vs. those not on COCs. J Sex Med 2006; 3: 878-82. (Pubitemid 44269543)
11. Bitzer J. Contraception and sexuality. Ther Umsch 1994; 51: 110-4.
12. McCoy N L, Matyas J R. Oral contraceptives and sexuality in university women. Arch Sex Behav 1996; 25: 73-90. (Pubitemid 26052237)
13. Graham CA, Ramos R, Bancroft J, et al. The effects of steroidal contraceptives on the well-being and sexuality of women: A double-blind, placebo-controlled, twocentre study of combined and progestogen-only methods. Contraception 1995; 52: 363-9. (Pubitemid 26004861)
14. Bancroft J, Loftus J, Long J S. Distress about sex: A national survey of women in heterosexual relationships. Arch Sex Behav 2003; 32: 193-208. (Pubitemid 38090835)
15. Bancroft J. Androgens and sexual function in men and women. In Bagatell CJ, Bremmer WJ, eds. Androgens in health and disease. Totowa, NJ: Humana Press 2003: 258-90.
16. Bell RJ, Donath S, Davison, SL, Davis, SR. Endogenous androgen levels and wellbeing: differences between preand postmenopausal women. Menopause 2006; 13: 65-71.
17. Davis SR, Davison S L, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005; 294: 91-6. (Pubitemid 41002843)
18. Guay A, Jacobson J, Munarriz R, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part B: Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction. Int J Impot Res 2004; 16: 121-9. (Pubitemid 38579456)
19. Adams DB, Gold AR, Burt AD. Rise in female initiated sexual activity at ovulation and its suppression by oral contraceptives. N Engl J Med 1978; 299: 1145-50. (Pubitemid 9065569)
20. Bitzer J, Tschudin S, Meier-Burgoa J, et al. Effects on the quality of life of a new oral contraceptive containing 30 mcg EE and 3 mg drospirenone (Yasmin). Praxis 2003; 92: 1177-84. (Pubitemid 44804359)
21. Caruso S, Agnello C, Intelisano G, et al. Sexual behavior of women taking low-dose contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception 2004; 69: 237-40. (Pubitemid 38224223)
22. Panzer C, Wise S, Fantini G, et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: A retrospective study in women with sexual dysfunction. J Sex Med 2006; 3: 104-13.
23. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001; 64: 51-8. (Pubitemid 32787098)
24. Wallwiener CW, Wallwiener LM, Seeger H, et al. Prevalence of sexual dysfunction and impact of contracep - tion in female German medical students. J Sex Med 2010; 7: 2139-48.
25. Alexander GM, Sherwin B B, Bancroft J, Davidson, DW. Testosterone and sexual behavior in oral contraceptive users and non-users: A prospective study. Horm Beh 1990; 24: 388-402. (Pubitemid 20319015)
26. Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 mg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005; 72: 19-23. (Pubitemid 40827113)
27. Caruso S, Iraci Sareri M, Agnello C, et al. Conventional versus extended-cycle oral contraceptives on the quality of sexual life: Comparison between two regimens containing 3 mg drospirenone and 20 mg ethinyl estradiol. J Sex Med 2011; 8: 1478-85.
28. Davis AR, Castano PM. Oral contraceptives and libido in women. Annu Rev Sex Res 2004; 15: 297-320. (Pubitemid 41422842)
29. Gallo M F, Grimas D A, Schulz K F, Helmehorst F M. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103: 359-73.
30. Gracia C R, Sammel M D, Charlesworth S, et al. Sexual function in first-time contraceptive ring and contraceptive patch users. Fertil Steril 2010; 93: 21-8.
31. Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception - oral versus intravaginal - on the sexual life of women and their partners. Hum Reprod 2005; 20: 1100-6. (Pubitemid 40667862)
32. Li RH, Lo SS, Teh DK, et al. Impact of common contraceptive methods on quality of life and sexual function in Hong Kong Chinese women. Contraception 2004; 70: 474-82. (Pubitemid 39488204)
33. Redmond G, Godwin A J, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: Methodological issues and adverse event incidence. Contraception 1999; 60: 81-5.
34. Schaffir J. Hormonal contraception and sexual desire: A critical review. J Sex Marital Ther 2006; 32: 305-14. (Pubitemid 43995226)
35. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005; 31: 1-20. (Pubitemid 40070592)
36. Rycroft-Malone J, McCormack B, Hutchinson AM, et al. Realist synthesis: illustrating the method for implementation research. Implementation Sci 2012; 7: 33. doi: 10. 1186/1748-5908-7-33.
37. Bancroft J, Davidson D W, Warner P, Tyrer G. Androgens and sexual behaviour in women using oral contraceptives. Clin Endocrinol 1980; 12: 327-40. (Pubitemid 10131708)
38. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual syndromes. Psychoneuroendocrinology 1993; 18: 273-81. (Pubitemid 23156341)
39. Alexander G M, Sherwin B B. Sex steroids, sexual behavior, and selection attention for erotic stimuli in women using oral contraceptives. Psychoneuroendocrinology 1993; 18: 91-102. (Pubitemid 23096420)
40. Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial comparing effect of drospirenone and gestodene to sexual desire and libido. J Med Assoc Thai 2006; 89: S17-22. (Pubitemid 46193154)
41. Graham CA, Bancroft J, Doll HA, et al. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? Psychoneuroendocrinology 2007; 32: 246-55. (Pubitemid 46420398)
42. Greco T, Graham CA, Bancroft J, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: A comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007; 76: 8-17. (Pubitemid 46950885)
43. Caruso S, Rugolo S, Agnello C, et al. Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. J Sex Med 2009; 6: 3376-84.
44. Lee M, Morgan M, Rapkin A. Clitoral and vulvar vestibular sensation in women taking 20 mcg ethinyl estradiol combined oral contraceptives: A preliminary study. J Sex Med 2011; 8: 213-8.
45. Strufaldi R, Pompei LM, Steiner ML, et al. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception 2010; 82: 147-54.
46. Heiman JR, Rupp H, Janssen E, et al. Sexual desire, sexual arousal and hormonal differences in premenopausal US and Dutch women with and without low sexual desire. Horm Behav 2011; 59: 772-9.
47. Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med 2011; 8: 2841-50.
48. Battaglia C, Battaglia B, Mancini F, et al. Sexual behaviour and oral contraception: Pilot study. J Sex Med 2012; 9: 550-7.
49. Fucs G B, Coutinho E M. Treatment of diminished sexual response associated with the use of oral contraceptives. Reproduccion 1975; 2: 97-104.
50. Gambrell R D Jr, Bernard D M, Sanders B I, et al. Changes in sexual drives of patients on oral contraceptives. J Reprod Med 1976; 17: 165-71.
51. Erkkola R, Hirvonen E, Luikku J, et al. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990; 1: 61-5. (Pubitemid 20155762)
52. Bancroft J, Sherwin BB, Alexander GM, et al. Oral contraceptives, androgens, and the sexuality of young women: II. The role of androgens. Arch Sex Behav 1991; 20: 121-35.
53. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006; 74: 220-23. (Pubitemid 44175362)
54. Skrzypulec V, Drosdzol A. Evaluation of the quality of life and sexual functioning of women using a 30- mg ethinylestradiol and 3-mg drospirenone combined oral contraceptives. Eur J Contracept Reproduct Health Care 2008; 13: 49-57. (Pubitemid 351271856)
55. Warner P, Bancroft J. Mood, sexuality, oral contraceptives and the menstrual cycle. J Psychosom Res 1988; 32: 417-27. (Pubitemid 19033962)
56. Martin-Loeches M, Ortí R M, Monfort, M, et al. A comparative analysis of the modification of sexual desire of users of oral hormonal contraceptives and intrauterine contraceptive devices. Eur J Contracept Reprod Health Care 2003; 8: 129-34. (Pubitemid 37372404)
57. Brucker C, Hedon B, The H S, et al. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception 2010; 81: 501-9.
58. Heskamp M S, Schramm G AK. Efficacy of the low dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: Physical and emotional benefits. Contraception 2010; 81: 49-56.
59. Panzer C, Guay A, Goldstein I. Do oral contraceptives produce irreversible effects on women's sexuality?: A reply. J Sex Med 2006; 3: 568-70.
60. Bancroft J, Hammond G, Graham C. Do oral contraceptives produce irreversible effects on women's sexuality? J Sex Med 2006; 3: 567.
61. Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438.
62. Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5801-7. (Pubitemid 38033054)
63. Weiner C L, Primeau M, Ehrmann D A. Androgen and mood dysfunction in women: Comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004; 66: 356-62. (Pubitemid 38668404)
64. Shifren JL, Braunstein G D, Simon J A, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New Engl J Med 2000; 343: 682-8.
65. Persky H, Dreisbach L, Miller W, et al. The relation of plasma androgen levels to sexual behaviors and attitudes of women. Psychosom Med 1982; 44: 305-19. (Pubitemid 12034612)
66. Meston CM, Buss DM. Why humans have sex. Arch Sex Behav 2007; 36: 477-507. (Pubitemid 47106402)
67. Stuckey B GA. Female sexual function and dysfunction in the reproductive years: The influence of endogenous and exogenous sex hormones. J Sex Med 2008; 5: 2282-90.